pharmaceutical daily news

Sanofi reported €762m of net income in the second quarter 2018, after net sales of €8,176 million, down 5.7% on a reported basis.

4D pharma showed that specific single bacterial strains from the human gut microbiota can serve as therapeutic inhibitors of the human enzyme histone deacetylase (HDAC), which is particularly relevant for disease areas involving host epigenetic aberrations.

Beximco Pharmaceuticals got approval from the US Food and Drug Administration (FDA), for its Nadolol tablets, a generic equivalent of Bristol-Myers Squibb’s Corgard, for hypertension and chest pain, angina pectoris. 

Apricus Biosciences will merge with Seelos Therapeutics, Inc., a privately-held biotechnology company, in an all-stock transaction, it announced on Monday, and will focus on bringing to shelves central nervous system (CNS) therapeutics.

Destiny Pharma’s first of two Phase 1 safety clinical studies of testing XF-73’s potential to cause dermal irritation, as Destiny’s lead candidate for the prevention of post-surgical staphylococcal infections, brought good news with positive results, which support the potential of XF compounds in dermal infection indications and also reinforce the target

PureTech Health’s new internal programme focused on treating central nervous system (CNS) disorders via modulation of the brain’s lymphatic system, based on the work of Jonathan Kipnis, from Centre for Brain Immunology and Glia, at the University of Virginia School of Medicine, was published in Nature.

WuXi STA Pharmaceutical’s Active Pharmaceutical Ingredient (API) production site in China, at Jinshan, Shanghai, has passed its fourth inspection from the U.S. Food and Drug Administration (USFDA). WuXi STA is the first CDMO in China that is approved to supply commercial APIs for innovative drugs by regulatory agencies in the USA,

PureTech Health’s independent affiliate, resTORbio reported positive topline results from its Phase 2b clinical study with TORC1 inhibitor, that enrolled 652 elderly patients at increased risk of death related with respiratory tract infections (RTIs).